Q-VANT thanks the will of patients and subjects involved in the development of immunizations, without whom no vaccines would be authorized.
Developing new vaccines represents a lengthy, intense and resource challenge, incentivizing multiple actors to collaborate from the design to the approval of the vaccine.
Q-VANT Biosciences welcomes inquiries and seeks collaborations with the industry, academics, and public health in support of the development of vaccines incorporating saponin adjuvants.
Open-access to sustainable, scaling-up manufacturing
Saponin-based adjuvants have traditionally been derived from Quillaja bark and for licensing but are now accessible from sustainable and cost-effective biomass and for open-access. Q-VANT’s technology ensures a secure supply of saponins, as well as the guarantee that no Quillaja trees are felled. QS-21 and other saponin adjuvants can be directly sourced from Q-VANT secure manufacturing process and renewable biomass sourcing. Q-VANT’s manufacturing facilities are located in United States and Chile, ready for a further rapid expansion.
Affordable adjuvant for public health programs.
Q-VANT’s philosophy brings QS-21 at an affordable cost for public health immunization programs, including those for Malaria and other tropical diseases.
Grants and resources
- NIH: 75N93023C00045 – Development of novel oral Saponin/DMLT Adjuvant (SDA), Tulane University (Elizabeth Norton) in collaboration with Q-VANT and PATH.
R&D opportunities
-
Q-VANT seeks collaborations and support for the research and development of immunizations incorporating saponin adjuvants.
-
Technical support on formulation and applications.
-
Benefit from Q-VANT’s capabilities for the exploration and development of specific saponin fractions.
-
Cooperation for grant funding applications.
